Patents Examined by Julie Wu
  • Patent number: 11945861
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: April 2, 2024
    Assignee: IMMUNOQURE AG
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Patent number: 11939386
    Abstract: Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 26, 2024
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Ke Yu, Jingkang Shen, Tao Meng, Jinpeng Pei, Lanping Ma, Xin Wang, Rui Jin, Zhiyan Du, Lin Chen, Ting Yu, Yongliang Zhang
  • Patent number: 11939381
    Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: March 26, 2024
    Assignee: Eli Lilly and Company
    Inventors: Stephen J. Demarest, Yiqing Feng, Juqun Shen, Yang Shen, Stephanie Marie Truhlar
  • Patent number: 11919960
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: March 5, 2024
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
  • Patent number: 11912747
    Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 27, 2024
    Assignee: TARGIMMUNE THERAPEUTICS AG
    Inventors: Alexander Levitzki, Yael Langut
  • Patent number: 11891449
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 6, 2024
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen
  • Patent number: 11884729
    Abstract: The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: January 30, 2024
    Assignee: ApitBio, Inc
    Inventors: Hyo Jeong Hong, Heesu Chae, Jisu Hong
  • Patent number: 11884723
    Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 30, 2024
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Vanessa Gauttier, Caroline Mary, Sabrina Pengam, Bernard Vanhove
  • Patent number: 11879012
    Abstract: This invention relates generally to a method of inhibiting epithelial cell proliferation including the treatment of conditions associated with aberrant epithelial cell proliferation in mammals, including animals and humans. The present invention is particularly relevant for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 23, 2024
    Assignees: METRO NORTH HOSPITAL AND HEALTH SERVICE
    Inventors: Peter Gillies, Damien G. Harkin, Neil A. Richardson
  • Patent number: 11866500
    Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: January 9, 2024
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
  • Patent number: 11851494
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: December 26, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
  • Patent number: 11834483
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: December 5, 2023
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jared Lopes, Heather C. Losey, Raymond J. Winquist
  • Patent number: 11834498
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: December 5, 2023
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
  • Patent number: 11820821
    Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 21, 2023
    Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
  • Patent number: 11802161
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 31, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • Patent number: 11801265
    Abstract: The present disclosure relates to a method for preparing NK cells and an application thereof in treatment of a cancer. The present disclosure provides a pharmaceutical composition prepared from NK cells and a monoclonal antibody of CD105, which can be used for the treatment of colorectal cancer and has a good application prospect.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: October 31, 2023
    Assignee: SINO UNITED (BEIJING) BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Aijie Qi, Shaobo Li, Ailei Qi
  • Patent number: 11801307
    Abstract: Disclosed herein, are antibody-polymer-drug conjugates. The conjugate comprises a targeting moiety, one or more polymers, and one or more therapeutic agents. Also described herein, are compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 31, 2023
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Jiyuan Yang, Jindrich Kopecek, Libin Zhang, Yixin Fang
  • Patent number: 11795225
    Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: October 24, 2023
    Assignee: MedImmune Limited
    Inventors: Krista Lynne Kinneer, Gareth Charles Davies, David Gareth Rees, Jennifer Louise Percival-Alwyn, John Edward Andrews, Jon Chesebrough
  • Patent number: 11793867
    Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: October 24, 2023
    Assignee: BIONTECH US INC.
    Inventor: Vikram Juneja
  • Patent number: 11795236
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: October 24, 2023
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe